HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy
Biomolecules and Biomedicine · 2025
DOI: 10.17305/bb.2025.13398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2025. Verfasst von Erkan Topkan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Türkiye. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Chemoradiotherapy, Nasopharyngeal Neoplasms, C-Reactive Protein. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nasopharyngeal carcinoma (NPC) is an aggressive malignancy of the head and neck that is often diagnosed at a locally advanced stage (LANPC). In such cases, intensity-modulated radiotherapy combined with concurrent chemoradiotherapy (CCRT) is the standard treatment; however, the occurrence of distant metastasis and treatment failure remains prevalent. This study evaluates the prognostic significance of a novel composite score that combines hemoglobin levels and the C-reactive protein-to-albumin ratio (HCAR) in LANPC patients undergoing CCRT. We conducted a retrospective analysis of 233 LANPC patients treated with intensity-modulated radiotherapy and platinum-based CCRT from 2011 to 2020. Receiver operating characteristic curve analysis determined pretreatment hemoglobin (Hb) and C-reactive protein-to-albumin ratio (CAR) cut-offs of 11.0 g/dL and 3.0, respectively, which were utilized to create a three-tiered HCAR score: HCAR-0 (Hb ≥11.0 g/dL and CAR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Türkiye.
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Türkiye.
- Department of Radiation Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Türkiye.
- Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Türkiye.
Zitieren
APA
Topkan, E., Somay, E., Ozturk, D., & Selek, U. (2025). HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2025.13398
Vancouver
Topkan E, Somay E, Ozturk D, Selek U. HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Biomolecules and Biomedicine. 2025. doi:10.17305/bb.2025.13398
BibTeX
@article{Topkan2025,
author = {Topkan, Erkan and Somay, Efsun and Ozturk, Duriye and Selek, Ugur},
title = {HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy},
journal = {Biomolecules and Biomedicine},
year = {2025},
doi = {10.17305/bb.2025.13398}
}
EUVIMED